• DRAMP ID

    • DRAMP18069
    • Sequence

    • ╬▒helix
    • Sequence Name

    • rBPI21(Neuprex)
    • Description

    • a human bactericidal permeability protein derivative
    • Activity

    • Antibacterial,Antiendotoxin(bacterial membranes)
    • Medical use

    • meningococcaemia;prophylactic treatment of infectious complications from post-traumatic bleeding (in 842 patients)
    • Stage of Development

    • Phase III(Failure)
    • Comments

    • In 1996, a pilot study conducted in 26 children with meningococcal septicaemia showed the remarkable efficacy of Neuprex, with only one death (vs 22% mortality based on historical data). This spectacular result has since then not been confirmed in a phase III trial involving over 2,200 pediatric cases of meningococcaemia [38, 49]. A phase III trial aimed at evaluating the efficacy of Neuprex for the prophylactic treatment of infectious complications from post-traumatic bleeding (in 842 patients) also showed no benefit
    • Company

    • Xoma Ltd(Berkeley, CA, USA)
    • Target Organism

      • No MICs found on DRAMP database
    • Reference

      • Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability increasing protein in children with severe meningococcal sepsis. Lancet (1997).(PMID: 9371168)
      • Bactericidal/permeability increasing protein(rBPI-21) in patients with hemorrhage due to trauma: results of a multicenter phase II clinical trial. Trauma (1999)(PMID: 10217232)